Navigation Links
DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC

the future use of orBec® for gastrointestinal GVHD include the risks that: because orBec® did not achieve statistical significance in its primary endpoint in the pivotal Phase 3 clinical study (i.e. a p-value of less than or equal to 0.05), the Oncologic Drug Advisory Committee ("ODAC") appointed by the FDA voted that the data supporting orBec® did not show substantial evidence of efficacy by a margin of 7 to 2 for the treatment of GI GVHD, although the FDA is not bound by ODAC's decision, the FDA may not consider orBec® approvable based upon existing studies, orBec® may not show therapeutic effect or an acceptable safety profile in future clinical trials, if required, or could take a significantly longer time to gain regulatory approval than DOR expects or may never gain approval; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; or orBec® may not gain market acceptance; and others may develop technologies or products superior to orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Form 10-QSB and Form 10-KSB. DOR assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, and changes in circumstances or for any other reason.

--------------------------------------------------------------------------------


Company Contact:
Evan Myrianthopoulos
Chief Financial Officer
(786) 425-3848
www.dorbiopharma.com


SOURCE: DOR BioPharma, Inc.


'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
6. AVI BioPharma Reports Positive Pre-Clinical Influenza Data
7. Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b
8. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:12/1/2008)...O, Dec. 1 TargeGen has announced t...from a multi-center, US-based clinical,trial of T... been scheduled at,the 2008 American Society of H... presentation are as follows:, Title: ...vailable, JAK2-Selective I...
(Date:12/1/2008)...stinence is still the best policy , , ROCH...new study from Mayo Clinic finds the use of the dr...holic hepatitis, an acute inflammation of the live...results of the study are published in the December...urnal.org/ ). , , VIDEO ALERT: Additional ...
(Date:12/1/2008)...O, Dec. 1 Vical Incorpor... of a $1.0 million milestone payment from Merck &a...of a Phase I clinical trial of an investigational ...accine is based on Vical,s DNA gene delivery techn...iptase (hTERT). hTERT is the subject of separate l...
(Date:11/27/2008)...y finds the majority of acute lymphoblastic leukem... at the time of diagnosis , , MEMPHIS, Tenn...t St. Jude Children,s Research Hospital have ident...lls of children with acute lymphoblastic leukemia ...hway to designing treatments for ALL relapse in ch...
Breaking Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 2St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse 3Progress toward new storage media 8631 1Progress toward new storage media 8631 2Anadys Pharmaceuticals to Present at Bio Investor Forum 27824 1Anadys Pharmaceuticals to Present at Bio Investor Forum 27824 2MU researchers advance health communication for at risk populations 27821 1MU researchers advance health communication for at risk populations 27821 2Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 1Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 2Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 3Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference 3354 4
... Since the level of blood oxygenation can be an es... of hemoglobin levels in the clinical setting is o...o incorporate sophisticated technology into easily...several manufacturers offer prompt assessment of h..., Calif., says that its HemoCue Hemoglobin Test Sy...
... Although it may still seem radically innovative i...ated production in the manufacturing sector had be..., for example, automated lines fabricate sub-assem...an oversight. The result has been vastly improved ...ive returns in profit and productivity. These days...
Other Medicine Technology:Hemoglobin Testing at the Point of Care 2Hemoglobin Testing at the Point of Care 3Lab Automation Networks Proliferating 2Lab Automation Networks Proliferating 3Lab Automation Networks Proliferating 4
(Date:12/2/2008).... 2 In response to the commentary ...ent Respiratory Infections, and the Vitamin D Defi...well known supplement experts, Nordic Naturals ann...no threat or compromise to consumers and actually ...low in natural Vitamin A. According to Karin Yien,...
(Date:12/2/2008)...re/ -- The Healthcare group at Frost & Sulliva... to announce that it will be,hosting an interacti...diology,Markets on 11 December 2008 at 3pm GMT. ,...h/20081117/FSLOGO ) , With most diagnostic ...ndors in Europe are faced with an immense challeng...
(Date:12/2/2008)...Dec. 2 Internationally recognized,...nvited speaker for this,year,s annual meeting of ... (Photo: http://www.newscom.com/cgi-bin/prnh/200... minimally invasive (or ,Goldilocks,) anesthesia,...K 101, minimally invasive,anesthesia for minimall...
(Date:12/2/2008)... World Wide Dictation Service, one of the premier...cription, and legal dictation transcription, has ..., a non-profit organization geared to the betterme...r families throughout Lower Westchester County, Ne...WEB) December 3, 2008 -- World Wide Dictation Serv...
Breaking Medicine News(10 mins):Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Will Diagnostic Cardiology Vendors Look to Product Innovation? 2Health News:World Wide Dictation Service Teams up with TMATT for Local Thanksgiving Community Dinner 2
...ment has repeated its plea to doctors over prescri...could save ?85 millions in the coming year if GPs/... Primary Care Trusts (PCTs) can prescribe generic ...mvastatin, which are two of five ‘statin’ drugs th...
...exercise by doing household chores like dusting, m...east cancer, suggests a new study.// The research... women from nine European countries and found that... cancer protective than playing sport, reported th...
...s at the National Institutes of Health have discov...steogenesis //Imperfecta--a disorder that weakens ...lts from a genetic defect in a protein involved in...ted gene contains the information for cartilage as...
... your high blood pressure might just be your infla...dence suggests that inflammation, a part of the im...r, Alzheimer’s and diabetes, may also help transla...ressure. “There is a concept that hypertension is...
Other Medicine News:Health News:Researchers Discovered the Gene Responsible for Brittle Bone Disease 2Health News:Researchers Discovered the Gene Responsible for Brittle Bone Disease 3Health News:Inflammatory Genes Linked to Salt-Sensitive Hypertension 2Health News:Inflammatory Genes Linked to Salt-Sensitive Hypertension 3
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: